Page 11234..1020..»

STEM Animal Health completes first shipment of bluestem™ oral care products to PetSmart® Canada

By Dr. Matthew Watson

WINNIPEG, Manitoba, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. announces that STEM Animal Health Inc., has shipped its first order of bluestem™ products to PetSmart® Canada, Canada largest specialty pet retailer of services and solutions for the lifetime needs of pets. Bluestem™ oral care products will be distributed to all 150 stores and will be available via PetSmart®’s online store.

Continue reading here:
STEM Animal Health completes first shipment of bluestem™ oral care products to PetSmart® Canada

To Read More: STEM Animal Health completes first shipment of bluestem™ oral care products to PetSmart® Canada
categoriaGlobal News Feed commentoComments Off on STEM Animal Health completes first shipment of bluestem™ oral care products to PetSmart® Canada | dataSeptember 1st, 2021
Read All

Pyxis Oncology Appoints Pamela Yanchik Connealy as Chief Financial Officer

By Dr. Matthew Watson

– Veteran biotech executive adds financial and operational expertise to growing Pyxis team – – Veteran biotech executive adds financial and operational expertise to growing Pyxis team –

Go here to read the rest:
Pyxis Oncology Appoints Pamela Yanchik Connealy as Chief Financial Officer

To Read More: Pyxis Oncology Appoints Pamela Yanchik Connealy as Chief Financial Officer
categoriaGlobal News Feed commentoComments Off on Pyxis Oncology Appoints Pamela Yanchik Connealy as Chief Financial Officer | dataSeptember 1st, 2021
Read All

Tauriga Sciences, Inc. Initiates Clinical Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum

By Dr. Matthew Watson

The Company’s Proposed Cannabidiol Delivery System Utilizes its Proprietary Cannabidiol (“CBD”) Infused Chewing Gum Platform

Excerpt from:
Tauriga Sciences, Inc. Initiates Clinical Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum

To Read More: Tauriga Sciences, Inc. Initiates Clinical Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum
categoriaGlobal News Feed commentoComments Off on Tauriga Sciences, Inc. Initiates Clinical Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum | dataSeptember 1st, 2021
Read All

Quanta to Present at the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021

By Dr. Matthew Watson

ALCESTER, United Kingdom and BEVERLY, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today John E. Milad, Chief Executive Officer, will present at the 2021 Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021, at 9:20 a.m. Eastern Time.

Read more from the original source:
Quanta to Present at the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021

To Read More: Quanta to Present at the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021
categoriaGlobal News Feed commentoComments Off on Quanta to Present at the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021 | dataSeptember 1st, 2021
Read All

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

By Dr. Matthew Watson

Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) -- SYDNEY, AUSTRALIA – 31 August 2021 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to advise its Chinese partner for eftilagimod alpha (“efti” or “IMP321”), EOC Pharma (“EOC”) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China.

Visit link:
Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

To Read More: Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
categoriaGlobal News Feed commentoComments Off on Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline | dataSeptember 1st, 2021
Read All

ECMOHO Limited Announces Second Quarter 2021 Unaudited Financial Results

By Dr. Matthew Watson

SHANGHAI, China, Aug. 31, 2021 (GLOBE NEWSWIRE) -- ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO”, “we” or the “Company”), a leading integrated solutions provider in the health and wellness market in China, today announced its unaudited financial results for the second quarter ended June 30, 2021.

More here:
ECMOHO Limited Announces Second Quarter 2021 Unaudited Financial Results

To Read More: ECMOHO Limited Announces Second Quarter 2021 Unaudited Financial Results
categoriaGlobal News Feed commentoComments Off on ECMOHO Limited Announces Second Quarter 2021 Unaudited Financial Results | dataSeptember 1st, 2021
Read All

Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

By Dr. Matthew Watson

MARLBOROUGH, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be virtually participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

Follow this link:
Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

To Read More: Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Akoya Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference | dataSeptember 1st, 2021
Read All

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences

By Dr. Matthew Watson

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Kevin R. Lind, Longboard’s President & Chief Executive Officer, will present virtually in a fireside chat format at two upcoming investor conferences: Citi’s 16th Annual BioPharma Virtual Conference and H.C. Wainwright’s 23rd Annual Global Investment Conference.

See the original post here:
Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences

To Read More: Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences | dataSeptember 1st, 2021
Read All

Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce…

By Dr. Matthew Watson

LAS VEGAS, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, has launched Ultimate Brain Nutrients RELIEF™, a proprietary, patent-pending natural formulation that provides relief from symptoms often associated with migraine headaches, while increasing brain and cognitive activation.

See more here:
Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce...

To Read More: Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce…
categoriaGlobal News Feed commentoComments Off on Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce… | dataSeptember 1st, 2021
Read All

Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy

By Dr. Matthew Watson

Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021 Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021

Go here to see the original:
Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy

To Read More: Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy
categoriaGlobal News Feed commentoComments Off on Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy | dataSeptember 1st, 2021
Read All

XORTX Announces New Clinical Advisory Board Member

By Dr. Matthew Watson

CALGARY, Alberta, Aug. 31, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of one new member to the Company’s clinical advisory board, Dr. Charles Edelstein.

Read this article:
XORTX Announces New Clinical Advisory Board Member

To Read More: XORTX Announces New Clinical Advisory Board Member
categoriaGlobal News Feed commentoComments Off on XORTX Announces New Clinical Advisory Board Member | dataSeptember 1st, 2021
Read All

Total number of shares and voting rights in Zealand Pharma at August 31, 2021

By Dr. Matthew Watson

Company announcement – No. 54 / 2021

See the article here:
Total number of shares and voting rights in Zealand Pharma at August 31, 2021

To Read More: Total number of shares and voting rights in Zealand Pharma at August 31, 2021
categoriaGlobal News Feed commentoComments Off on Total number of shares and voting rights in Zealand Pharma at August 31, 2021 | dataSeptember 1st, 2021
Read All

Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

By Dr. Matthew Watson

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference. The presentation will be available on-demand starting Monday, September 13, at 7:00 A.M. (ET).

Go here to read the rest:
Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

To Read More: Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
categoriaGlobal News Feed commentoComments Off on Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | dataSeptember 1st, 2021
Read All

Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium

By Dr. Matthew Watson

Company announcement – No. 55 / 2021

Link:
Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium

To Read More: Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium
categoriaGlobal News Feed commentoComments Off on Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium | dataSeptember 1st, 2021
Read All

Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

By Dr. Matthew Watson

- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 -

Here is the original post:
Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

To Read More: Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results
categoriaGlobal News Feed commentoComments Off on Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results | dataSeptember 1st, 2021
Read All

Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

By Dr. Matthew Watson

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

More here:
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

To Read More: Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
categoriaGlobal News Feed commentoComments Off on Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | dataSeptember 1st, 2021
Read All

10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

By Dr. Matthew Watson

PLEASANTON, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

See more here:
10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

To Read More: 10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on 10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference | dataSeptember 1st, 2021
Read All

Certara to Participate in Upcoming Investor Conferences

By Dr. Matthew Watson

PRINCETON, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the following virtual investor conferences:

Follow this link:
Certara to Participate in Upcoming Investor Conferences

To Read More: Certara to Participate in Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Certara to Participate in Upcoming Investor Conferences | dataSeptember 1st, 2021
Read All

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®…

By Dr. Matthew Watson

Basel, September 01, 2021 — Novartis has reached a commercial agreement with the NHS in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to address elevated LDL-C in eligible patients with ASCVD across England.

Here is the original post:
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®...

To Read More: World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®…
categoriaGlobal News Feed commentoComments Off on World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®… | dataSeptember 1st, 2021
Read All

Recording of the 6 months 2021 Investor Conference Webinar

By Dr. Matthew Watson

On August 31, 2021 JSC Olainfarm organized its Investor Conference Webinar. During the webinar J?nis Buks, the chairman of the Management Board and J?nis Leimanis, member of the Management Board analyzed the financial results of 6 months 2021 and informed about other recent activities within the company.

See the original post here:
Recording of the 6 months 2021 Investor Conference Webinar

To Read More: Recording of the 6 months 2021 Investor Conference Webinar
categoriaGlobal News Feed commentoComments Off on Recording of the 6 months 2021 Investor Conference Webinar | dataSeptember 1st, 2021
Read All

Page 11234..1020..»